⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16499782 | 0.85 | — | — | |
| SCHEMBL20415293 | 0.83 | CYP1A2 (0.50) | — | |
| SCHEMBL537445 | 0.81 | CYP1A2 (0.54) | — | |
| SCHEMBL28312759 | 0.81 | CYP1A2 (0.54) | — | |
| SCHEMBL11574906 | 0.81 | EPHX1 (0.37) | — | |
| SCHEMBL10061726 | 0.77 | — | — | |
| SCHEMBL16013278 | 0.77 | — | — | |
| SCHEMBL18928714 | 0.77 | — | — | |
| SCHEMBL21643789 | 0.77 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL22775016 | 0.77 | SMN1; SMN2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-20240131169-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-113646304-B | Microbiocidal thiazole derivatives | 先正达农作物保护股份公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20240025854-A1 | HYDROXY-PYRIDINALDOXIME SCAFFOLDS | ETAT FRANÇAIS, SERVICE DE SANTÉ DES ARMÉES REPRÉSENTÉ PAR LE DÉLÉGUÉ GÉNÉRAL DE L’ARMEMENT (FR) | 2024-01-25 | — | — | US | disclosed |
| CN-117241668-A | Microbiocidal quinoline/quinoxaline benzothiazine derivatives | 先正达农作物保护股份公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| EP-4284790-A1 | TARGETED DELIVERY OF 1, 2, 4, 5-TETRAOXANE COMPOUNDS AND THEIR USES | Westlake University (CN) | 2023-12-06 | — | — | EP | disclosed |
| US-20140171404-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| WO-2013169401-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013149136-A1 | ISOXAZOLE β-LACTAMASE INHIBITORS | CUBIST PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2411364-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411367-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010109115-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109123-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |